Stearns G

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: September 2009.

Drs. Galatian, Stearns, and Grau report no conflict of interest. The authors discuss off-label use of active charcoal, cholestyramine, dronabinol, etanercept, gabapentin, mirtazapine, nalmefene hydrochloride, naloxone hydrochloride, naltrexone hydrochloride, paroxetine hydrochloride, rifampicin, sertraline hydrochloride, tacrolimus ointment, thalidomide, ursodeoxycholic acid, UVA1 therapy, and UVB phototherapy for pruritus. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Galatian was a student, Dr. Stearns was an intern, and Dr. Grau was Assistant Clinical Professor, all from the Department of Dermatology, The University of Oklahoma, Oklahoma City. Dr. Galatian currently is a resident, The University of Oklahoma. Dr. Stearns currently is a resident, State University of New York, Syracuse. Dr. Grau currently is a dermtologist, Saints Dermatology, Oklahoma City, and Volunteer Assistant Clinical Professor, The University of Oklahoma.

Alison Galatian, MD; Gillian Stearns, MD; Renee Grau, MD

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: September 2009.

Drs. Galatian, Stearns, and Grau report no conflict of interest. The authors discuss off-label use of active charcoal, cholestyramine, dronabinol, etanercept, gabapentin, mirtazapine, nalmefene hydrochloride, naloxone hydrochloride, naltrexone hydrochloride, paroxetine hydrochloride, rifampicin, sertraline hydrochloride, tacrolimus ointment, thalidomide, ursodeoxycholic acid, UVA1 therapy, and UVB phototherapy for pruritus. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Galatian was a student, Dr. Stearns was an intern, and Dr. Grau was Assistant Clinical Professor, all from the Department of Dermatology, The University of Oklahoma, Oklahoma City. Dr. Galatian currently is a resident, The University of Oklahoma. Dr. Stearns currently is a resident, State University of New York, Syracuse. Dr. Grau currently is a dermtologist, Saints Dermatology, Oklahoma City, and Volunteer Assistant Clinical Professor, The University of Oklahoma.

Alison Galatian, MD; Gillian Stearns, MD; Renee Grau, MD

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: September 2009.

Drs. Galatian, Stearns, and Grau report no conflict of interest. The authors discuss off-label use of active charcoal, cholestyramine, dronabinol, etanercept, gabapentin, mirtazapine, nalmefene hydrochloride, naloxone hydrochloride, naltrexone hydrochloride, paroxetine hydrochloride, rifampicin, sertraline hydrochloride, tacrolimus ointment, thalidomide, ursodeoxycholic acid, UVA1 therapy, and UVB phototherapy for pruritus. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis^® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Galatian was a student, Dr. Stearns was an intern, and Dr. Grau was Assistant Clinical Professor, all from the Department of Dermatology, The University of Oklahoma, Oklahoma City. Dr. Galatian currently is a resident, The University of Oklahoma. Dr. Stearns currently is a resident, State University of New York, Syracuse. Dr. Grau currently is a dermtologist, Saints Dermatology, Oklahoma City, and Volunteer Assistant Clinical Professor, The University of Oklahoma.

Alison Galatian, MD; Gillian Stearns, MD; Renee Grau, MD